B-Cell Dysfunction Drives Immune Escape in iCCA : Gut | June 2026

Introduction:

Intrahepatic cholangiocarcinoma (iCCA) is one of the most aggressive primary liver malignancies, characterized by poor survival and limited therapeutic options. Although recent advances in immunotherapy have offered new treatment opportunities, response rates remain modest. A major obstacle is the highly complex and immunosuppressive tumor microenvironment, which limits effective antitumor immunity. While T-cell biology has been extensively studied in iCCA, the role of B lymphocytes within the tumor microenvironment remains incompletely understood.

Problem Statement:

B cells are increasingly recognized as important regulators of antitumor immunity, yet their functional significance in iCCA is unclear. Understanding how tumor-associated factors influence B-cell differentiation and activity may identify novel biomarkers of treatment response and uncover new therapeutic strategies to improve immunotherapy outcomes.

Summary:

This comprehensive translational study provides important insights into the role of B cells in the immune landscape of iCCA. The investigators demonstrated that B cells located in adjacent non-tumorous tissues frequently formed mature tertiary lymphoid structures (TLS), which were associated with more favorable clinical outcomes. In contrast, B cells infiltrating the tumor itself were scarce, immature, and exhibited impaired immune function with prominent immunosuppressive characteristics. Mechanistic analyses revealed that interactions with tumor cells and cancer-associated fibroblasts actively suppress B-cell maturation and effector activity. The cytokines IL-6 and TGF-β emerged as key mediators of this dysfunction, and simultaneous blockade of these pathways restored B-cell activation and differentiation in experimental models. Importantly, patients with higher levels of circulating BAFFR-positive B cells and expanded B-cell clonotypes experienced better responses to chemoimmunotherapy, suggesting potential predictive biomarkers for treatment selection. These findings highlight B cells as previously underappreciated contributors to immune regulation in iCCA and suggest that restoring B-cell function may enhance antitumor immunity. The study provides a strong rationale for developing therapeutic strategies aimed at reversing B-cell suppression and promoting mature TLS formation, potentially improving the effectiveness of immunotherapy in this difficult-to-treat malignancy.